Is It OCD? A Screening Guide for Providers

This post is for clinicians and referral sources who want a faster way to tell whether the pattern in front of them is OCD. It is a summary of screening points and first-line care, not a clinical protocol. The people you refer need an evaluation by a clinician trained in OCD.

Why screening matters

The International OCD Foundation reports that, on average, it takes over seven years from symptom onset to an accurate OCD diagnosis. Shame is part of the reason. Many patients never volunteer intrusive thoughts, especially violent or taboo ones. Many have only internal compulsions, such as mental review or silent counting, that no one can see. Ask directly.

Diagnosis comes from a clinical interview, usually anchored by a structured tool such as the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). No scan or lab test confirms OCD.

Six screening questions

1. Is there an intrusive, unwanted thought or urge? Not a preoccupation or a preference.
2. Does the person recognize, at least some of the time, that it is excessive or irrational? Insight sits on a spectrum, so "some of the time" counts.
3. Is there a compulsion, visible or entirely mental, aimed at neutralizing the distress?
4. Does the compulsion bring only brief relief, with the obsession returning as strong or stronger?
5. Is there a cost in time, distress, or daily functioning? The older benchmark is more than an hour a day.
6. Is the pattern ego-dystonic? Is the person fighting it, or living comfortably inside it?

A repeated behavior is not a compulsion by appearance alone. Function decides. Ask what the behavior is for. If it is done out of dread, to head off something feared, with distress when interrupted, it may be a compulsion. If it feels useful or satisfying, it may be a preference.

OCD or OCPD?

Rigidity and perfectionism do not rule OCD in. People with obsessive-compulsive personality disorder (OCPD) tend to be exacting and control-oriented, and they usually experience those traits as ego-syntonic. They often draw a sense of competence or mastery from the orderliness, not only dread.

Pinto and colleagues (2014) compared people with OCD, OCPD, both, and neither. Both disorders showed functional impairment, but only the groups with OCD reported true obsessions. OCPD without OCD was marked by a strong capacity to delay reward. OCD alone did not differ much from controls on that measure. Intrusiveness and ego-dystonic distress are what you are screening for. The two can also co-occur, so orderly traits do not exclude OCD.

Find the specific feared outcome

"Checking" or "order" is a surface description. Exposure work does not land without the fear underneath. Ask gently and keep asking.

A patient who will not turn left on a walk may not know why at first. Pressed kindly, they may reach: if I turn left, someone specific will die. Treatment targets that fear, not the general idea that left turns are bad. The specific fear also becomes the target of the exposure hierarchy.

With checking, ask about doubt as well as behavior. Many patients remember the event clearly and still cannot trust the memory. Treat that distrust as part of the target.

First-line treatment

Exposure and response prevention (ERP) is a first-line, best-supported psychotherapy for OCD (Goodman, Storch, & Sheth, 2021). The patient approaches the feared stimulus, in person or in imagination, lets anxiety rise, and blocks the compulsion. The aim is not to calm the patient down.

In Foa and colleagues (2005), a randomized, placebo-controlled trial in the American Journal of Psychiatry, ERP alone produced a larger drop in Y-BOCS scores than clomipramine alone. Starting both together did not outperform ERP by itself.

Homework adherence matters. In a small study of 30 adults, Simpson and colleagues (2012) found that adherence to exposure homework during acute treatment predicted OCD severity six months later.

An adequate SRI trial is the established first-line medication option. These include fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram, escitalopram, and clomipramine. Full effect usually takes eight to twelve weeks, often at higher doses than used for depression. Medication decisions belong with a licensed prescriber.

Document first-line treatment before moving to augmentation strategies. Hold off on those until you have shown that first-line care was not enough.

What to screen alongside OCD

• Anxiety disorders and depression
• Substance use. Alcohol and cannabis misuse can occur, sometimes as an attempt to self-soothe
• Hoarding disorder
• Body dysmorphic disorder
• Body-focused repetitive behaviors
• In children with sudden onset after an infection, ask about PANDAS or PANS

When to consider referral for augmentation or neuromodulation

If a patient has not responded to adequate ERP and an adequate SRI trial, refer for a specialist opinion. At a summary level, the options include:

• Augmentation. Adding a low-dose antipsychotic has the most solid evidence, and is particularly useful with a co-occurring tic disorder. Glutamate-modulating agents have been studied, but well-controlled trials have often failed to beat placebo.
• Deep transcranial magnetic stimulation (deep TMS). It has FDA clearance for OCD, based on a randomized trial showing about a 38 percent response rate against 11 percent for sham stimulation (Carmi et al., 2019).
• Deep brain stimulation (DBS). Reserved for severe, treatment-resistant cases. It holds an FDA Humanitarian Device Exemption for intractable OCD. It is adjustable and reversible.

Refer to Eden Valley

Eden Valley, the clinical practice of Revolution Youth, Inc. in Burlington, Vermont, accepts OCD referrals for ages 5 and up. Our OCD clinicians have completed ERP trainings through The Knowledge Tree and the Cognitive Behavioral Institute.

We accept records with a signed release by mail, fax, or secure email. To start a referral, use our contact page.

This post is educational and does not replace clinical judgment. If a patient is in crisis, call or text 988.

Sources

• Foa, E.B., Liebowitz, M.R., Kozak, M.J., et al. (2005). Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. American Journal of Psychiatry, 162(1), 151-161.
• Simpson, H.B., Marcus, S.M., Zuckoff, A., Franklin, M., & Foa, E.B. (2012). Patient adherence to cognitive-behavioral therapy predicts long-term outcome in obsessive-compulsive disorder. Journal of Clinical Psychiatry, 73(9), 1265-1266.
• Pinto, A., Steinglass, J.E., Greene, A.L., Weber, E.U., & Simpson, H.B. (2014). Capacity to delay reward differentiates obsessive-compulsive disorder and obsessive-compulsive personality disorder. Biological Psychiatry, 75(8), 653-659.
• Carmi, L., Tendler, A., Bystritsky, A., et al. (2019). Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder: A prospective multicenter randomized double-blind placebo-controlled trial. American Journal of Psychiatry, 176(11), 931-938.
• Goodman, W.K., Storch, E.A., & Sheth, S.A. (2021). Harmonizing the neurobiology and treatment of obsessive-compulsive disorder. American Journal of Psychiatry, 178(1), 17-29.